- Volume 25 Issue 4
The effect of a new treatment is proven through the comparison of a new treatment with placebo; however, the number of parent non-inferiority trials tends to grow proportionally to the number of active controls. In a non-inferiority trial a new treatment is approved by proof that the new treatment is not inferior to an active control; however, both additional assumptions and historical trials are needed to show (through the comparison of the new treatment with the active control in a non-inferiority trial) that the new treatment is more efficacious than a putative placebo. The two different methods of using the historical data: frequentist principle method and meta-analytic method. This paper discusses the statistical methods and different Type I error rates obtained through the different methods employed.
Assay sensitivity;constancy assumption;Type I error
- Blackwelder, W. C. (1982). "Proving the null hypothesis" in clinical trials, Controlled Clinical Trials, 3, 345-353. https://doi.org/10.1016/0197-2456(82)90024-1
- D'Agostino, R. B., Massaro, J. M. and Sullivan, L. M. (2003). Non-inferiority trials: Design concepts and issues - the encounters of academic consultants in statistics, Statistics in Medicine, 22, 169-186.
- Fleming, T. R. (2008). Current issues in non-inferiority trials, Statistics in Medicine, 27, 317-332. https://doi.org/10.1002/sim.2855
- Hasselblad, V. and Kong, D. F. (2001). Statistical methods for comparison to placebo in active-control trials, Drug Information Journal, 35, 435-449. https://doi.org/10.1177/009286150103500212
- Holmgren, E. B. (1999). Establishing equivalence by showing that a specified percentage of the effect of the active control over placebo in maintained, Journal of Biopharmaceutical Statistics, 9, 651-659. https://doi.org/10.1081/BIP-100101201
- Hung, H.-M., Wang, S.-J. and O'Neill, R. (2007). Issues with statistical risks for testing methods in noninferiority trial without a placebo arm, Journal of Biopharmaceutical Statistics, 17, 201-213. https://doi.org/10.1080/10543400601177343
- Hung, H. M., Wang, S. J. and O'Neill, R. (2009). Challenges and regulatory experiences with non-inferiority trial design without placebo arm, Biometrical Journal, 51, 324-334. https://doi.org/10.1002/bimj.200800219
- Hung, H.-M., Wang, S.-J.,Tsong, Y., Lawrence, J. and O'Neill, R. (2003). Some fundamental issues for noninferiority testing in active controlled trials, Statistics in Medicine, 22, 213-225.
- ICH E10 (2001). Choice of control group and related issues in clinical trials.
- Kang, S. H. (2010). Biostatistical Methods for New Drug Development, Freeacademy, Seoul.
- Kang, S. H. and Ryu, Y. (2011). The adjustment of the type I error rate in non-inferiority trials with - margin approach: Each of two different new drugs is approved with two independent trials with the same active control, Journal of Biopharmaceutical Statistics, 21, 498-510. https://doi.org/10.1080/10543406.2010.482683
- Kang, S. H. and Tsong, Y. (2010). Strength of evidence of non-inferiority trials - the adjustment of the type I error rate in non-inferiority trials with the synthesis method, Accepted by Statistics in Medicine, 29, 1477-1487.
- Leber, P. D. (1989). Hazards of inference: The active control interpretation, Epilepsia, 30, S57-S63. https://doi.org/10.1111/j.1528-1157.1989.tb05816.x
- Temple, R. and Ellenberg, S. S. (2000). Placebo-controlled trials and active- controlled trials in the evaluation of new treatment, part I: ethical and scientific issues, Annals of Interna Medicine, 133, 455-463. https://doi.org/10.7326/0003-4819-133-6-200009190-00014
- Tsong, Y. (2007). The utility of active-controlled noninferiority / equivalence trials in drug development, International Journal of Pharmaceutical Medicine, 21, 225-233. https://doi.org/10.2165/00124363-200721030-00005
- Tsong, Y., Wang, S.-J., Hung, H.-M. and Cui, L. (2003). Statistical issues on objective, design and analysis of noninferiority active-controlled clinical trial, Journal of Biopharmaceutical Statistics, 13, 29-41. https://doi.org/10.1081/BIP-120017724
- U.S. FDA (2010). Guidance for Industry: Non-Inferiority Clinical Trials (draft guidance)
- Wang, S.-J. and Hung, H.-M. (2002). Utility and pitfalls of some statistical methods in active controlled clinical trials, Controlled Clinical Trials, 23, 15-28. https://doi.org/10.1016/S0197-2456(01)00155-6
- Wang, S.-J. and Hung, H.-M. (2003). Assessing treatment efficacy in non-inferiority trials, Controlled Clinical Trials, 24, 147-155. https://doi.org/10.1016/S0197-2456(02)00304-5
- Wang, S. Y. and Kang, S. H. (2012). Strength of evidence of non-inferiority trials with the two confidence interval method with random margin, Journal of Biopharmaceutical Statistics, In press
Supported by : National Research Foundation of Korea(NRF)